The most promising clinical responses to PD-1 blockade have been seen in classical Hodgkin lymphoma (cHL) and primary mediastinal B cell lymphoma (PMBL) with up to 87% overall response rate (ORR) detected in relapsed/refractory (R/R) cHL (3). The gene discussed is PDCD1; the disease is classic Hodgkin lymphoma.